<DOC>
	<DOCNO>NCT02328612</DOCNO>
	<brief_summary>Phase I , randomize , parallel group , placebo control , unicentric , interventional study . Thirty two healthy male volunteer age 18-35 year randomize eASCs placebo group meet inclusion criterion 3:1 ratio . The treatment administration infuse intravenously follow group randomization : - First arm : 250,000 cells/kg - Second arm : 1 million cells/kg - Third arm : 4 million cells/kg - Fourth arm : placebo accord weight . An hour end eASCs administration , subject give intravenous dose LPS . Subjects allow leave even deem clinically stable investigator .</brief_summary>
	<brief_title>Randomized , Parallel Group , Placebo Control , Unicentric , Interventional Study Assess Effect Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells Human Response Lipopolysaccharyde Human Volunteers</brief_title>
	<detailed_description>Medicinal product Suspension expand adipose-derived allogeneic adult stem cell ( eASCs ) single dose 250,000 cells/kg , 1 million cells/kg 4 million cells/kg intravenous infusion suspension Ringer 's lactate solution . Control Placebo ( Ringer 's lactate solution ) Objectives To investigate effect eASCs inflammatory response intravenous LPS human . Design Phase I , randomize , parallel group , placebo control , unicentric , interventional study . Thirty two healthy male volunteer age 18-35 year randomize eASCs placebo group meet inclusion criterion 3:1 ratio . The treatment administration infuse intravenously follow group randomization : - First arm : 250,000 cells/kg - Second arm : 1 million cells/kg - Third arm : 4 million cells/kg - Fourth arm : placebo accord weight . An hour end eASCs administration , subject give intravenous dose LPS . Subjects allow leave even deem clinically stable investigator .</detailed_description>
	<criteria>A subject eligible inclusion study follow criterion apply : 1 . Healthy , determine responsible physician , base medical evaluation include medical history , physical examination laboratory test carry within 28 day prior administration eASCs ( applicable ) LPS . A subject clinical abnormality laboratory parameter outside reference range may include investigator judge find unlikely introduce additional risk factor interfere study procedure 2 . Male age 18 35 year , inclusive time signing inform consent 3 . Male subject ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage activity conception possible study medication least 28 day take last dose study medication 4 . Must understand voluntarily sign informed consent form prior conduct study related assessment/procedures . Capable give write informed consent able comply requirement restriction list informed consent form . Subjects meet follow exclusion criterion enrol study : 1 . Subject major illness past 3 month significant chronic medical illness investigator would deem unfavourable enrolment , include inflammatory disease 2 . Subjects history malignancy 3 . Significant concurrent , uncontrolled medical condition include , limited , renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , neurological , cerebral psychiatric disease , evidence demyelinate disease 4 . Subject use tobacco product 5 . Subject history , within 3 year , drug abuse ( include benzodiazepine , opioids , amphetamine , cocaine , THC , methamphetamine ) 6 . History alcoholism and/or drink 5 unit alcohol per day 7 . Any clinically relevant abnormality note 12lead ECG judge investigator average QTc &gt; 450 msec 8 . The subject receive investigational product within three month prior day 1 current study 9 . Use prescription nonprescription drug herbal dietary supplement within 6 month unless opinion investigator medication interfere study procedure compromise subject safety 10 . Transfusion blood blood product within 6 month prior inclusion study . 11 . Subject difficultly donate blood accessibility vein leave right arm . 12 . Subject donate 350 mL blood last 3 month 13 . Body mass index &gt; 28 kg/m2 14 . Presence severe bleed thrombotic disorder 15 . History known pulmonary embolism know secondary antiphospholipid syndrome 16 . Subjects know suspect able comply study protocol ( e.g . due alcoholism , drug dependency psychological disorder ) 17 . Known allergy hypersensitivity antibiotic , HSA , DMEM , material bovine origin , Ringer 's Lactate Solution 18 . Any issue , opinion investigator , could harmful subject compromise interpretation data .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>